Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2022 / May / My MIGS of Choice, with Ken Lin
Glaucoma Research & Innovations Business and Entrepreneurship Practice Management

My MIGS of Choice, with Ken Lin

When I was asked about my favorite MIGS device, it was an easy question to answer: Trabectome!

By Ken Lin 5/24/2022 2 min read

Share

In 2015, I co-authored a paper that reported the safety and efficacy of the Trabectome as a method for reducing IOP in patients after failed glaucoma shunt surgery. During our study, we found patients’ IOP – 12 months after surgery – to be markedly reduced from their preoperative values (1), results that have since been corroborated by other studies (2). Additionally, the Trabectome has also been shown to have long-term success in contending with tube shunts, significantly improving visual acuity in the majority of patients, eight years after surgery (3). Although many of these patients continue to require topical medications, the results still indicate the promise of the Trabectome; the alternative would have been the placement of another glaucoma tube shunt or trabeculectomy.

I practice in a busy academic setting and, as such, receive many referrals for uveitic steroid-induced glaucoma. The etiology of rising IOP in the disease is primarily from the trabecular meshwork, and the Trabectome electrosurgical blade has been shown in many electron microscopy images to achieve meshwork ablation and exposure of the backwall of the Schlemm’s canal very cleanly and accurately. In addition, uveitic glaucoma patients tend to be younger and the Trabectome averts the need for these patients to undergo more invasive procedures, such as trabeculectomy and glaucoma drainage implants, which also come with lifetime risks of infection and exposure.

Another thing to take into consideration is patient satisfaction, which – in my experience – is high when performing irrigating goniectomy using the Trabectome. The surgical procedure is quick, taking only a few minutes, with faster vision recovery when compared with the tube shunt. It can be performed as a standalone procedure or in combination with cataract surgery. I personally appreciate being able to do all of my Trabectome cases with only topical anesthesia, which is unlike glaucoma drainage devices that require retrobulbar or sub-Tenon anesthesia. Patients require fewer post-op visits – a crucial benefit and not only in a pandemic.

If you were to draw a Venn diagram of MIGS devices, taking into consideration the factors of ease of use, variety of indications that can be treated, magnitude of post-operative care, hardware needed, and flexibility to be used with or independent of cataract surgery, you would likely find the Trabectome in the center. The device’s versatility allows me to provide enduring IOP reductions across the spectrum of glaucoma patients – and that makes it my choice MIGS.

Would you like to tell our readers about your favorite tool or device? Email your views to edit@theophthalmologist.com or leave a comment below.

References

  1. S Mosaed et al., “Results of Trabectome surgery following failed glaucoma tube shunt implantation: cohort study,” Medicine (Baltimore), 94, e1045 (2015). PMID: 26222842.
  2. P Ngai et al., “Outcome of primary trabeculotomy ab interno (Trabectome) surgery in patients with steroid-induced glaucoma,” Medicine (Baltimore), 95, e5383 (2016). PMID: 27977576.
  3. RE Bendel, MT Patterson, “Long-term effectiveness of Trabectome (ab-interno trabeculectomy) surgery,” J Curr Glaucoma Pract, 12, 119 (2018). PMID: 31354204.

About the Author(s)

Ken Lin

Associate Clinical Professor, the Director of Medical Education of the Ophthalmology School of Medicine at the University of California, Irvine, USA.

More Articles by Ken Lin

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: